Search Results - "Heilig, C.E."

3431 Vorinostat in locally advanced and metastastic soft tissue sarcomas - results of a multi-center phase II trial (SAHA-1) of the German Sarcoma and GIST Working Group (AIO) by Schmitt, T, Mayer-Steinacker, R, Mayer, F, Grünwald, V, schütte, J, Hartmann, J.T, Kasper, B, Hüsing, J, Hajda, J, Ottawa, G, Heilig, C.E, Ho, A.D, Egerer, G

Get full text

2318P Value of broad molecular profiling for cancer diagnosis by Werstein, L.V.A., Heilig, C.E., Teleanu, M-V., Hüllein, J., Singh, M., Bauer, S., Kindler, T., Klauschen, F., Brandts, C.H., Rieke, D.T., Illert, L., Börries, M., Kreutzfeldt, S., Horak, P., Hübschmann, D., Lipka, D.B., Glimm, H., Hartmann, W., Fröhling, S.

Get full text

131O A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort by Rübsam, M., Rheinnecker, M., Hutter, B., Fröhlich, M., Heilig, C.E., Paramasivam, N., Oleś, M., Ball, C., Glimm, H., Hlevnjak, M., Zapatka, M., Lichter, P., Fröhling, S., Schlenk, R.F., Hübschmann, D.

Get full text

1936P Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling by Renner, M., Oleś, M., Paramasivam, N., Schneider, A., Heilig, C.E., Modugno, C., Herremans, C., Mock, A., Lipka, D., Bauer, S., Kindler, T., Brandts, C.H., Keilholz, U., Boerries, M., Kuster, B., Hübschmann, D., Schlesner, M., Glimm, H., Schlenk, R.F., Fröhling, S.

Get full text

487P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies by Heilig, C.E., Teleanu, M-V., Bhatti, I.A., Richter, S., Siveke, J.T., Wagner, S., Kopp, H-G., Kindler, T., Illert, L., Golf, A., Dormann, K., Benner, A., Süsse, H., Freitag, A., Von Kalle, C., Glimm, H., Hübschmann, D., Fröhling, S., Schlenk, R.F.

Get full text

1490MO CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601) by Teleanu, M-V., Heilig, C.E., Hamacher, R.W., Bauer, S., Mayer-Steinacker, R., Gaidzik, V.I., Horak, P., Lanz, L-M., Muskatewitz, T., Süsse, H., Freitag, A., von Hornung, M., Wacker, L., Von Kalle, C., Barth, T., Fröhling, S., Schlenk, R.F.

Get full text

1940P Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials by Schlenk, R.F., Oleś, M., Bauer, S., Kindler, T., Klauschen, F., Brandts, C.H., Rieke, D.T., Illert, L., Börries, M., Heining, C., Horak, P., Bitzer, M., Dirksen, U., Sparber-Sauer, M., Teleanu, M-V., Kreutzfeldt, S., Glimm, H., Hübschmann, D., Heilig, C.E., Fröhling, S.

Get full text

187P Ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity: First results from the CRAFT trial by Heilig, C.E., Singh, M., Teleanu, M-V., Desuki, A., Kindler, T., Bitzer, M., Baier, B.D., Kunzmann, V., von Bubnoff, N., Süsse, H., Heiligenthal, L., Steindorf, K., Benner, A., Kreutzfeldt, S., Heining, C., Horak, P., Hübschmann, D., Glimm, H., Fröhling, S., Schlenk, R.F.

Get full text

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers by Jahn, A., Rump, A., Widmann, T.J., Heining, C., Horak, P., Hutter, B., Paramasivam, N., Uhrig, S., Gieldon, L., Drukewitz, S., Kübler, A., Bermudez, M., Hackmann, K., Porrmann, J., Wagner, J., Arlt, M., Franke, M., Fischer, J., Kowalzyk, Z., William, D., Weth, V., Oster, S., Fröhlich, M., Hüllein, J., Valle González, C., Kreutzfeldt, S., Mock, A., Heilig, C.E., Lipka, D.B., Möhrmann, L., Hanf, D., Oleś, M., Teleanu, V., Allgäuer, M., Ruhnke, L., Kutz, O., Knurr, A., Laßmann, A., Endris, V., Neumann, O., Penzel, R., Beck, K., Richter, D., Winter, U., Wolf, S., Pfütze, K., Geörg, C., Meißburger, B., Buchhalter, I., Augustin, M., Aulitzky, W.E., Hohenberger, P., Kroiss, M., Schirmacher, P., Schlenk, R.F., Keilholz, U., Klauschen, F., Folprecht, G., Bauer, S., Siveke, J.T., Brandts, C.H., Kindler, T., Boerries, M., Illert, A.L., von Bubnoff, N., Jost, P.J., Metzeler, K.H., Bitzer, M., Schulze-Osthoff, K., von Kalle, C., Brors, B., Stenzinger, A., Weichert, W., Hübschmann, D., Fröhling, S., Glimm, H., Schröck, E., Klink, B.

“…Germline variant evaluation in precision oncology opens new paths toward the identification of patients with genetic tumor risk syndromes and the exploration…”
Get full text

1533P Gene expression-based prediction of pazopanib benefit in sarcomas by Lassmann, A., Heilig, C.E., Mughal, S.S., Pirmann, S., Mock, A., Andresen, C., Aybey, B., Bauer, S., Brandts, C., Horak, P., Lipka, D., Kreutzfeldt, S., Teleanu, M.V., Heining, C., Brors, B., Glimm, H., Hübschmann, D., Fröhling, S.

Get full text

Community-driven development of a modified progression-free survival ratio for precision oncology trials by Mock, A., Heilig, C.E., Kreutzfeldt, S., Hübschmann, D., Heining, C., Schröck, E., Brors, B., Stenzinger, A., Jäger, D., Schlenk, R.F., Glimm, H., Fröhling, S., Horak, P.

Get full text

Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial by Kreutzfeldt, S., Apostolidis, L., Oles, M., Horak, P., Heilig, C.E., Heining, C., Hutter, B., Klink, B., Lamping, M., Uhrig, S., Stenzinger, A., Winkler, E.C., Wiedenmann, B., Jäger, D., Brors, B., Schröck, E., Keilholz, U., Pavel, M.E., Glimm, H., Fröhling, S.

Get full text

Comprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German Cancer Consortium by Horak, P., Kreutzfeldt, S., Mock, A., Heining, C., Heilig, C.E., Möhrmann, L., Uhrig, S., Hübschmann, D., Beck, K., Richter, D., Schlenk, R.F., Klink, B., Hutter, B., Weichert, W., Stenzinger, A., Schröck, E., Brors, B., Glimm, H., Fröhling, S.

Get full text

1979TiP - Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring dna repair deficiencies by Heilig, C.E., Hübschmann, D., Kopp, H.-G., Metzeler, K.H., Richter, S., Hermes, B., von Bubnoff, N., Kindler, T., Siveke, J., Wagner, S., Ochsenreither, S., Süße, H., Brors, B., Benner, A., Jäger, D., Von Kalle, C., Glimm, H., Gröschel, S., Fröhling, S., Schlenk, R.F.

“…Genomic aberrations affecting the repair of DNA double-strand breaks by homologous recombination (HR) are found in various cancers and result in sensitivity to…”
Get full text

Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring dna repair deficiencies by Heilig, C.E., Hübschmann, D., Kopp, H.-G., Metzeler, K.H., Richter, S., Hermes, B., von Bubnoff, N., Kindler, T., Siveke, J., Wagner, S., Ochsenreither, S., Süße, H., Brors, B., Benner, A., Jäger, D., Von Kalle, C., Glimm, H., Gröschel, S., Fröhling, S., Schlenk, R.F.

Get full text

Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia by Balss, J, Thiede, C, Bochtler, T, Okun, J G, Saadati, M, Benner, A, Pusch, S, Ehninger, G, Schaich, M, Ho, A D, von Deimling, A, Krämer, A, Heilig, C E

“…Mutations in isocitrate dehydrogenases (IDHs) 1 and 2 frequently occur in acute myeloid leukemia (AML) and result in the production of the oncometabolite d…”
Get full text

99P Fibroblast activation protein alpha (FAP) as theranostic target in solitary fibrous tumor by Hamacher, R.W., Pabst, K.M., Cheung, P.F., Heilig, C.E., Hüllein, J., Liffers, S-T., Schaarschmidt, B.M., Costa, P., Kessler, L., Falkenhorst, J., Glimm, H., Umutlu, L., Schuler, M.H.H., Hübschmann, D., Bauer, S., Fröhling, S., Herrmann, K., Siveke, J., Schildhaus, H-U., Fendler, W.

Get full text

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial by Heilig, C.E., Horak, P., Kreutzfeldt, S., Teleanu, V., Mock, A., Renner, M., Bhatti, I.A., Hutter, B., Hüllein, J., Fröhlich, M., Uhrig, S., Süße, H., Heiligenthal, L., Ochsenreither, S., Illert, A.L., Vogel, A., Desuki, A., Heinemann, V., Heidegger, S., Bitzer, M., Scheytt, M., Brors, B., Hübschmann, D., Baretton, G., Stenzinger, A., Steindorf, K., Benner, A., Jäger, D., Heining, C., Glimm, H., Fröhling, S., Schlenk, R.F.

“…Approvals of cancer therapeutics are primarily disease entity specific. Current molecular diagnostic approaches frequently identify actionable alterations in…”
Get full text